REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Year Ended December 31,
(In thousands)	2022			2021			2020
Royalties - RELVAR/BREO	$	215,034		$	234,066		$	221,536
Royalties - ANORO		38,405			44,935			45,992
Royalties - TRELEGY(1)		72,029			126,688			73,089
Total royalties		325,468			405,689			340,617
Less: amortization of capitalized    fees paid		(13,823	)		(13,823	)		(13,823	)
Royalty revenue		311,645			391,866			326,794
Strategic alliance - MABA program		—			—			10,000
Total net royalty revenue	$	311,645		$	391,866		$	336,794

(1) The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.